Results 111 to 120 of about 4,626,170 (385)

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer

Cells, 2020
E2F transcription factors play critical roles in the cell cycle. Therefore, their activity is expected to reflect tumor aggressiveness and responsiveness to therapy.
M. Oshi, Hideo Takahashi, Y. Tokumaru, Li Yan, O. Rashid, M. Nagahashi, R. Matsuyama, I. Endo, K. Takabe   +8 more
semanticscholar   +1 more source

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. [PDF]

, 2014
PurposeThis article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clinical data relating to its use for human growth factor receptor 2 (HER2)-positive breast cancer, potential pathways of resistance, and ongoing studies ...
Hurvitz, Sara A, Olevsky, Olga, Sadeghi, Saeed   +2 more
core   +1 more source

Neoadjuvant therapy for esophageal cancer

World Journal of Gastrointestinal Oncology, 2014
Esophageal cancer is increasing in incidence more than any other visceral malignancy in North America. Adenocarcinoma has become the most common cell type. Surgery remains the primary treatment modality for locoregional disease. Overall survival with surgery alone has been dismal, with metastatic disease the primary mode of treatment failure after an ...
James P. Neifeld, Rachit D. Shah, Anthony D. Cassano   +2 more
openaire   +3 more sources

Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer

Advanced Science, EarlyView.
Dysregulated RNA splicing is an underappreciated molecular feature of cancer. By integrating murine and cellular models with patient specimens of lung adenocarcinoma, this study demonstrates that RAC1B, rather than RAC1A isoform, promotes tumorigenesis and presents a potent therapeutic target for lung cancer. Mechanistically, RAC1B preferentially binds
Yueren Yan, Ning Wang, Bowen Xing, Min Yang, Jun Shang, Yufang Bao, Lixing Xiao, Ningxia Zhang, Yunpeng Ren, Chunnan Liu, Yuting Chen, Han Han, Yunjian Pan, Lei Lv, Wei‐Xing Zong, Hongbin Ji, Changyou Zhan, Zefeng Wang, Haiquan Chen, Yongbo Wang   +19 more
wiley   +1 more source

Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy

Bioactive Materials, 2023
Surgical resection remains a mainstay in the treatment of malignant solid tumors. However, the use of neoadjuvant treatments, including chemotherapy, radiotherapy, phototherapy, and immunotherapy, either alone or in combination, as a preoperative ...
Xiaogang Qu, Dong Zhou, Jianpu Lu, Duotian Qin, Jun Zhou, Hai-Jun Liu   +5 more
doaj  

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +2 more sources

Blood Biomarker‐Based Predictive Indicator for Liver Metastasis in Alpha‐Fetoprotein‐Producing Gastric Cancer and Multi‐Omics Tumor Microenvironment Insights

Advanced Science, EarlyView.
Alpha‐fetoprotein‐producing gastric cancer (AFPGC), a rare and aggressive subtype of gastric cancer, presents a high risk of liver metastasis. This study introduces the ANLiM score, a blood biomarker‐based predictive indicator for assessing liver metastasis and immunotherapy response.
Yongfeng Ding, Yiran Chen, Jing Zhang, Qingrui Wang, Songting Zhu, Junjie Jiang, Chao He, Jincheng Wang, Laizhen Tou, Jingwei Zheng, Bicheng Chen, Sizhe Hu, Xiongfei Yu, Haohao Wang, Yimin Lu, Mei Kong, Yanyan Chen, Haiyong Wang, Haibin Zhang, Hongxia Xu, Fei Teng, Xian Shen, Nong Xu, Jian Ruan, Zhan Zhou, Jun Lu, Lisong Teng   +26 more
wiley   +1 more source

Validity of upfront surgery for patients with unsuspected lymph node metastasis in esophageal cancer: a propensity scoring matching study

Journal of Cardiothoracic Surgery, 2018
Background Although neoadjuvant therapy followed by esophagectomy is well-established as being superior to upfront esophagectomy when locoregional lymph node (LN) metastasis is present in esophageal cancer, upfront esophagectomy without neoadjuvant ...
Jae Kil Park, Jae Jun Kim, Seok Whan Moon, Deog Gon Cho   +3 more
doaj   +1 more source

Triple positive breast cancer. A distinct subtype? [PDF]

, 2015
Breast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exemplified by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal receptor (HR) expression.
A. Cassano, A. Michelotti, C. Botti, C. Natoli, D. Sergi, F. Conti, F. Izzo, I. Sperduti, L. D'Onofrio, L. D. Lauro, L. Mariani, L. Moscetti, L. Pizzuti, M. Barba, M. Maugeri Saccà, M. Mottolese, MARCHETTI, PAOLO, P. Vici, T. Gamucci, V. Rossi   +19 more
core   +1 more source

SF3A3 Drives Tumorigenesis in Endometrial Cancer by Enhancing c‐FOS Expression and Represents a Potential Therapeutic Target

Advanced Science, EarlyView.
The role of splicing factor 3A subunit 3 (SF3A3) in driving endometrial cancer (EC) progression and potential therapeutic interventions. SF3A3, a core component of the U2 small nuclear ribonucleoprotein (U2 snRNP), is upregulated in endometrial cancer (EC) and promotes tumor growth and cisplatin resistance. RNA‐binding protein immunoprecipitation (RIP)
Wei Yu, Yi Gu, Hengrui Zhang, Wunan Huang, Lei Sun, Liangjian Ma, Xiaolei Liang, Lexin Liu, Guiping Chen, Weihua Wang, Zhongkai Cao, Xue Li, Xiangjun Chen, Lidan Hu   +13 more
wiley   +1 more source